AlphaRose Therapeutics Acquires Alpha Anomeric SA

Altos Labs Acquires Dorian Therapeutics

May 23, 2025

Biotechnology

Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.

Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics

January 9, 2026

Biotechnology

Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.

Ampersand Capital Partners Invests in AnaBios Corporation

June 7, 2022

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.

Biotage AB Acquires ATDBio

October 20, 2021

Biotechnology

Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Oncodesign Services Acquires ZoBio; Eurazeo's Nov Santé Invests in Oncodesign

January 23, 2023

Biotechnology

Oncodesign Services, majority-held by ERES IV SLP (Edmond de Rothschild Private Equity), has acquired Dutch fragment-based drug discovery specialist ZoBio to strengthen its upstream Drug Discovery capabilities. Concurrently, Nov Santé Actions Non Cotées (managed by Eurazeo) has invested in Oncodesign Services to support external growth and the group's international expansion.